TD Cowen on Mirum Pharmaceuticals (MIRM): 'We continue to view shares as undervalued'

October 12, 2026 9:36 AM

TD Cowen analyst Joseph Thome reiterated a Buy rating and $140.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found